Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.1%

3 terminated out of 27 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

11%

3 trials in Phase 3/4

Results Transparency

33%

4 of 12 completed with results

Key Signals

4 with results80% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (13)
P 1 (5)
P 2 (6)
P 3 (3)

Trial Status

Completed12
Unknown8
Withdrawn3
Terminated3
Recruiting1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT07029178Phase 2Recruiting

Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis

NCT04483856Not ApplicableCompletedPrimary

Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.

NCT04067310Not ApplicableCompletedPrimary

Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.

NCT06133218Not ApplicableCompletedPrimary

Patient Reported Outcomes Using Mepitel Film During Radiotherapy

NCT05886673Not ApplicableUnknownPrimary

Development of a Protective Cream Against Radiodermatitis Caused by Radiotherapy.

NCT04013711Not ApplicableCompleted

Thermal Imaging to Evaluate Skin Toxicity From Radiotherapy

NCT05535452Not ApplicableUnknownPrimary

Photobiomodulation for Prevention of Radiodermatitis in Women With Breast Cancer Undergoing Adjuvant Radiotherapy

NCT01925651Not ApplicableCompleted

Clinical Trial of The Use of Bolus in Post Mastectomy Irradiation in Breast Cancer

NCT04692389Not ApplicableWithdrawnPrimary

Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.

NCT04593914Not ApplicableWithdrawnPrimary

A Novel Skin Barrier Protectant for Acute Radiodermatitis

NCT03924011Not ApplicableCompletedPrimary

Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy

NCT04059809Phase 2Completed

Photobiomodulation for Breast Cancer Radiodermatitis

NCT03255980Not ApplicableCompletedPrimary

Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®

NCT04617730Phase 1UnknownPrimary

Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.

NCT02247830Phase 3CompletedPrimary

Management Radiodermatitis in Patients With Breast or Head and Neck Cancer

NCT04239560Phase 3CompletedPrimary

Preventive Effect of Boron-based Gel on Radiation Dermatitis

NCT02922244Not ApplicableCompletedPrimary

Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients

NCT03557983Not ApplicableUnknownPrimary

Evaluation of Fenofibrate on Radiation-induced Skin Injury

NCT02534129Phase 1TerminatedPrimary

Topical Use of Difinsa53™ to Prevent Radiation Dermatitis

NCT02289365Phase 2UnknownPrimary

Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

Scroll to load more

Research Network

Activity Timeline